Mounjaro Side Effects: How Often They Happen and Which Ones Need a Call

    Short answer

    The most common Mounjaro side effects on its FDA label are nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and stomach pain. In type 2 diabetes trials, nausea was reported by 12% to 18% of adults versus 4% on placebo, mostly during dose increases. Severe stomach pain or allergic swelling needs urgent care.

    People on Mounjaro for type 2 diabetes often want to know whether what they feel is expected. The label says most nausea, vomiting and diarrhea happened during dose escalation and decreased over time. Below are the trial rates for each effect, the serious risks the label warns about, and the symptoms that call for your prescriber or emergency care. All figures come from the Mounjaro prescribing information, revised August 2026.

    Four things the Mounjaro label makes clear

    The short version, from the Mounjaro prescribing information, revised 08/2026.

    Nausea and diarrhea lead the list

    In the placebo-controlled trials in adults with type 2 diabetes, nausea was reported by 12% to 18% of people on Mounjaro compared with 4% on placebo. Diarrhea was reported by 12% to 17%, compared with 9% on placebo.

    Stomach effects rise with the dose

    Any stomach side effect was reported by 37.1%, 39.6% and 43.6% of people across the three doses studied, compared with 20.4% on placebo. The higher the dose in the trials, the more often these effects showed up.

    A small share stopped treatment

    Between 3.0% and 6.6% of people on Mounjaro stopped because of stomach effects, compared with 0.4% on placebo. Most people in the trials continued, but the label still lists the symptoms that need attention.

    The label lists serious risks too

    The label carries a boxed warning for thyroid C-cell tumors and lists pancreatitis, low blood sugar with insulin or a sulfonylurea, kidney injury, gallbladder disease and allergic reactions. Each one is explained further down this page.

    Common effects in the type 2 diabetes trials

    The first seven rows are the label's Table 1: side effects reported by at least 5% of people on Mounjaro, and more often than on placebo, in the pooled placebo-controlled trials in adults with type 2 diabetes. The burping row comes from the label's text on the same trials. The doses in the column headings are the label's trial arms, not a recommendation.

    Side effectPlaceboMounjaro 5 mgMounjaro 10 mgMounjaro 15 mg
    Nausea4%12%15%18%
    Diarrhea9%12%13%17%
    Decreased appetite1%5%10%11%
    Vomiting2%5%5%9%
    Constipation1%6%6%7%
    Indigestion (dyspepsia)3%8%8%5%
    Stomach pain4%6%5%5%
    Burping (eructation)0.4%3.0%2.5%3.3%

    Nausea and vomiting

    Nausea was reported by 12%, 15% and 18% of people at the three doses studied, versus 4% on placebo. Vomiting was reported by 5%, 5% and 9%, versus 2% on placebo.

    Diarrhea and constipation

    Diarrhea was reported by 12% to 17% of people on Mounjaro and by 9% on placebo. Constipation was reported by 6% to 7%, compared with 1% on placebo.

    Lower appetite

    Decreased appetite was reported by 5% to 11% of people on Mounjaro versus 1% on placebo. Eating less is part of how the medicine works, and the label counts it as a common effect.

    Indigestion, stomach pain and burping

    Indigestion was reported by 5% to 8% and stomach pain by 5% to 6%, compared with 3% and 4% on placebo. Burping, listed as eructation, was reported by 2.5% to 3.3% versus 0.4%, and gas and reflux were also more frequent than on placebo. More on the smell question in sulfur burps on a GLP-1.

    Injection site reactions and heart rate

    Injection site reactions were reported by 3.2% of people on Mounjaro compared with 0.4% on placebo (see GLP-1 injection site reactions). Average heart rate rose by 2 to 4 beats per minute, compared with 1 beat per minute on placebo.

    Serious warnings on the Mounjaro label

    These events are uncommon, but they are why a new or unusual symptom should not always be put down to the medicine.

    Boxed warning: thyroid C-cell tumors

    Tirzepatide caused thyroid C-cell tumors in rats, and it is not known whether Mounjaro does this in people. Anyone with a personal or family history of medullary thyroid carcinoma (MTC) or with MEN 2 should not use it. A lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath should be reported to your prescriber.

    Pancreatitis

    In clinical studies, acute pancreatitis was confirmed in 13 people on Mounjaro, a rate of 0.23 per 100 years of exposure, versus 0.11 in the comparison groups. The label describes severe stomach pain that may spread to the back, with or without vomiting, as the sign to act on.

    Low blood sugar with other diabetes medicines

    The risk of low blood sugar goes up when Mounjaro is used with insulin or a sulfonylurea. In the trial that added Mounjaro to basal insulin, blood sugar below 54 mg/dL was reported by 14% to 19% of people, compared with 13% on placebo.

    Kidney injury, gallbladder disease and allergic reactions

    Fluid loss from vomiting or diarrhea can lead to acute kidney injury, which the label lists as a warning. Gallbladder disease was reported by 0.6% of people on Mounjaro versus none on placebo, and serious allergic reactions such as anaphylaxis have been reported.

    Eye changes, anesthesia, pregnancy and birth control pills

    People with a history of diabetic retinopathy should be monitored for changes, and the label lists a risk of food or liquid entering the lungs during anesthesia or deep sedation. Based on animal studies, the label says Mounjaro may cause harm to an unborn baby, so tell your prescriber if you are pregnant or planning to be.

    Mounjaro can make birth control pills less reliable, so the label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Talk to your prescriber about which method fits you.

    When to get help

    This list follows the warnings and Medication Guide in the Mounjaro label. It is not a complete list and it is not medical advice: if something feels wrong, call.

    Emergency care

    Swelling of the face, lips, tongue or throat, trouble breathing, or a severe rash are signs of a serious allergic reaction and need emergency help. Severe stomach pain that does not go away, with or without vomiting, also needs urgent attention.

    Call your prescriber

    Contact your prescriber about any of these:

    • Nausea, vomiting or diarrhea that is severe or will not go away, or signs of dehydration.
    • Pain in the upper stomach, fever, yellowing of the skin or eyes, or clay-colored stools, which can be gallbladder signs.
    • Shakiness, sweating, dizziness, a fast heartbeat, hunger, headache, blurred vision, confusion or irritability, which can mean low blood sugar, especially with insulin or a sulfonylurea.
    • Any change in your vision, if you have type 2 diabetes.
    • A lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath.

    Before surgery or sedation

    Tell your care team you take Mounjaro before any planned surgery or procedure that uses anesthesia or deep sedation. The label asks patients to share this because slower stomach emptying can affect these procedures.

    Questions about your dose

    Questions about your dose, your schedule or a missed injection go to your prescriber, and your label has the official missed-dose instructions (our missed GLP-1 dose guide explains where to find them). This page shares label facts only and does not give dosing advice.

    How to report a side effect

    The label gives two contacts for reporting a suspected side effect: Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979), or the FDA's MedWatch program at 1-800-FDA-1088.

    Why the first weeks and each step-up feel different

    Knowing why an effect happens helps you describe it to your prescriber. Every point here comes from the label.

    Food leaves the stomach more slowly

    The label states that Mounjaro delays gastric emptying. Food staying in the stomach longer is linked with fullness, nausea and indigestion.

    Dose increases are when effects peak

    The label's schedule starts at 2.5 mg once weekly, with 2.5 mg increases after at least 4 weeks on a dose, as the prescriber directs. That is the label's schedule, not a plan for you: your prescriber sets yours. Most nausea, vomiting and diarrhea in the trials showed up during these increases and eased over time.

    Each weekly shot lasts for days

    The label gives an elimination half-life of about 5 days, so each injection stays active through much of the week. That helps explain why some people notice their symptoms follow a pattern after shot day. The tirzepatide half-life calculator shows what a 5-day half-life looks like.

    Children and teens saw more vomiting

    Mounjaro is also approved for children 10 and older with type 2 diabetes. In that trial, vomiting was reported by 12% to 16% and stomach pain by 15% to 22% of young patients, compared with 3% and 9% on placebo.

    From the makers of this guide

    Track how you feel week to week

    The label gives trial averages. Your prescriber needs your version: which symptoms, how strong, and how they fall around shot day.

    1. 01

      Built-in symptoms, each with a severity

      The side-effect tracker has built-in GLP-1 symptoms grouped by area, such as injection site, digestive and head and nerves, plus your own, each saved by day with how severe it was. A short daily check-in asks about food noise, side effects and mood, and you can add questions such as energy and sleep.

    2. 02

      Symptoms beside your shot history

      Your side-effect trend chart sits on the Dose tab beside your Mounjaro shot history, so nausea that shows up two days after every shot, or after a step-up, is easy to point to.

    3. 03

      An estimated medication level

      An estimated level chart on the same tab shows how your logged doses rise and fall across the week, which gives you something concrete to discuss with your prescriber.

    4. 04

      What you ate on rough days

      Log meals by photo scan, barcode or search in Nutrition, then look back at rougher days to notice which foods sat well and which did not.

    Download on the App StoreGet it on Google Play

    Share your log with your care team

    A symptom log is most useful in the room with your prescriber.

    A PDF report for your visit

    Pep AI builds a PDF report of your doses, injection sites, weight and daily meal totals. Open it on your phone at the appointment or send it ahead.

    Questions to bring

    Ask whether your pattern is expected, which symptoms should prompt a call, and how your diabetes medicines work together. Your prescriber decides whether anything changes.

    Keep the record going

    A quick entry each day keeps the record complete between visits, so the report is already up to date when the next appointment comes.

    Key takeaways

    • Nausea was reported by 12% to 18% of adults on Mounjaro in the type 2 diabetes trials, versus 4% on placebo.
    • Stomach effects rose with the dose and clustered during dose increases, then decreased over time.
    • 3.0% to 6.6% stopped Mounjaro because of stomach effects, versus 0.4% on placebo.
    • Mounjaro carries the boxed thyroid C-cell tumor warning; low blood sugar risk rises with insulin or a sulfonylurea.
    • Dose, schedule and missed-dose questions belong with your prescriber and your label.

    Bring your side effects, not just a memory of them.

    Pep AI logs your Mounjaro shots, symptoms with severity, meals and weight, and makes a PDF of your doses, sites, weight and meal totals. Download Pep AI on iPhone or Android.

    Download on the App StoreGet it on Google Play

    Frequently asked questions

    Keep reading

    Sources

    1. Mounjaro (tirzepatide) prescribing information and Medication Guide, Eli Lilly / FDA (revised 08/2026)
    2. MedWatch: The FDA Safety Information and Adverse Event Reporting Program

    This page summarizes the Mounjaro prescribing information (revised 08/2026). It is general information, not medical advice, and does not replace your prescriber or pharmacist. Pep AI is not affiliated with or endorsed by Eli Lilly and Company. If a symptom is severe, getting worse or worrying you, contact your healthcare provider. In an emergency, call 911.

    Published by the Pep AI team · Updated November 2026